Category - Developments

Developments

Zucara Therapeutics secures additional funding to develop ZT-01 for T2D

Closely-held Zucara Therapeutics received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes. “GlycoNet’s...

May 2, 2022

Developments

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...

May 2, 2022

Developments

Annovis Bio in pact with the National Institute on Aging

Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...

April 29, 2022

Developments

PharmaJet presents partner data on immunogenicity with needle-free systems

Closely-held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...

April 27, 2022

Developments

IntelGenx oral film for ED featured in WebMD

The current issue of WebMD features up-and-coming buccal film and buccal patch technologies to deliver drug via the inside lining of the cheek and highlights the sublingual delivery for erectile dysfunction from...

April 21, 2022

Developments

FDA rejects Ampio Pharma proposal for modified filing of Ampion

The FDA rejected Ampio Pharmaceuticals’ (NYSE American:AMPE) proposed modified intent-to-treat (mITT) population as the primary analysis population for evaluating efficacy in the AP-013 trial, and the acceptability of...

April 21, 2022

Developments

LENZ Therapeutics and JIXING in exclusive greater China license agreement

Closely-held LENZ Therapeutics entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment...

April 13, 2022

Developments

Numinus to acquire Novamind creating leader in psychedelic therapy, research

Numinus (TSX:NUMI; OTCQX:NUMIF) agreed to acquire Novamind (CSE:NM; OTCQB:NVMDF;FSE:HN2) in a stock swap, by way of a court-approved plan of arrangement, for total consideration of about $26.2-million (Canadian). The...

April 13, 2022

Developments

Altamira Therapeutics provides business update

Altamira Therapeutics (NASDAQ:CYTO) provided a business update as it repositions around RNA therapeutics and continues to progress towards upcoming key catalysts with its non-RNA legacy programs. “We are...

April 12, 2022

Developments

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

The International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming Altamira Therapeutics’ (NASDAQ:CYTO) positive research findings regarding the in vitro efficacy and safety of its drug...

April 11, 2022

Category - Developments

Subscribe